Although several new therapeutic approaches, such as anti-C-C chemokine receptor 4 (CCR4) antibodies and allogeneic hematopoietic stem cell transplantation (HSCT), have been established [7–9], the overall prognosis of aggressive-type ATLL patients remains unsatisfactory. Here, CCR4 is linked to adult T-cell leukemia/lymphoma.